OptimizeRx Secures Two Additional Enterprise Clients on Newly Integrated Digital Healthcare Platform
11 März 2020 - 1:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has secured
two additional enterprise-level engagements, expanding access for
two clients across the entire OptimizeRx platform.
“These two wins demonstrate continued traction in converting our
clients from individual solutions to enterprise platform
engagements, allowing them to benefit from a full set of solutions
across our network,” said OptimizeRx chief commercial
officer, Steve Silvestro. “They also reflect a growing broader
interest in enterprise engagements for our expanded platform, which
now covers all touchpoints throughout the patient care journey.
“The reason for this interest is simple: our enterprise
engagements produce strong results from improved interoperability
between our point-of-care and direct-to-patient communications,
which all works together to deliver better outcomes. Also, in these
times of limited travel, our digital healthcare platform supports
the flow of critical communications for industry and healthcare
providers regardless of their location.”
OptimizeRx’s newly integrated platform enables unprecedented
transparency into patient medication behavior and provides access
to patient-provider-pharma communication across the care continuum
and in a variety of care settings. Pharmaceutical companies,
healthcare providers (HCPs) and payers are now better able to
efficiently and effectively address patient medication
affordability and therapeutic adherence. This is largely due to
improvements in communication and increased level of digital health
messages transmitted between HCPs, manufacturers, patients and
payers.
According to company CEO, William Febbo: "We are very
pleased with our continued conversion of the pipeline of
enterprise-level opportunities. We believe our up-sell opportunity
of converting our existing clients from individual solutions to
enterprise platform engagements is over $100 million. While
naturally this will not be realized overnight, we are encouraged by
our progress and expect to see continued growth from our integrated
platform approach.”
“Such enterprise deals also enable us to increase our revenue
per customer, as well as provide a more predictable and consistent
revenue stream,” added Febbo. “As we address the industry need for
greater collaboration, we see our investments in technology,
channel, solutions and our sales team driving continued adoption of
our platform.”
About OptimizeRxOptimizeRx® (NASDAQ: OPRX), a
digital health company, connects pharmaceutical companies to
patients and providers, offering greater affordability, adherence
and brand awareness at the point-of-care. As the nation’s largest
digital platform connecting life sciences to the point-of-care,
OptimizeRx provides a direct channel for pharma companies, payers,
medtech, and medical associations to communicate with healthcare
providers right within their workflow and also directly to
patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half of the
ambulatory patient market with access to these benefits through
leading EHR platforms like Allscripts, Amazing Charts and Quest,
and directly via its mobile communications platform and digital
therapeutics SaaS platform.
For more information, follow the company on Twitter, LinkedIn or
visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra, Media
Relations ManagerTel (754) 245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both, CMATel
(949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024